Lynx1 Capital Management LP: TSCAN THERAPEUTICS INC (TCRX): Quarterly 13F Position History
As of Q1 2026, Lynx1 Capital Management LP reported 8,019,148 shares of TSCAN THERAPEUTICS INC (TCRX), worth $8.1M and representing 1.3% of its 13F equity book. The position first appeared in Q2 2023 and has been disclosed across 12 13F-HR filings in Pactolio's tracked window.
- 8,019,148Shares Held (Latest Filing)
- $8.1MReported Market Value (Latest Filing)
- 1.3%Portfolio Weight (% of 13F Equity Book)
- 0Quarter-over-Quarter Share Change
- +$80.2KQuarter-over-Quarter Value Change
- 8,019,148Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 12 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 8,019,148 | 0 | — | $8.1M | 1.3% | $1.0 |
| Q4 2025 | 8,019,148 | +161,801 | +2.1% | $8.0M | 1.6% | $1.0 |
| Q3 2025 | 7,857,347 | 0 | — | $14.3M | 2.9% | $1.8 |
| Q2 2025 | 7,857,347 | +2,500,000 | +46.7% | $11.4M | 3.3% | $1.4 |
| Q1 2025 | 5,357,347 | 0 | — | $7.4M | 2.6% | $1.4 |
| Q4 2024 | 5,357,347 | +132,747 | +2.5% | $16.3M | 6.1% | $3.0 |
| Q3 2024 | 5,224,600 | 0 | — | $26.0M | 9.2% | $5.0 |
| Q2 2024 | 5,224,600 | 0 | — | $30.6M | 11.1% | $5.8 |
| Q1 2024 | 5,224,600 | 0 | — | $41.5M | 10.8% | $7.9 |
| Q4 2023 | 5,224,600 | 0 | — | $30.5M | 12.0% | $5.8 |
| Q3 2023 | 5,224,600 | 0 | — | $13.4M | 8.8% | $2.6 |
| Q2 2023 | 5,224,600 | — | — | $13.1M | 8.6% | $2.5 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Lynx1 Capital Management LP first disclose a TCRX position in 13F-HR filings?
Lynx1 Capital Management LP first reported TSCAN THERAPEUTICS INC (TCRX) on its 13F-HR filing for the period ending 2023-06-30 (Q2 2023). The position has appeared on 12 reported quarters within Pactolio's tracked window.
What was Lynx1 Capital Management LP's most recent quarter-over-quarter share-count change in TCRX?
Lynx1 Capital Management LP held the same 8,019,148 shares of TCRX between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.
Does the implied price-per-share represent Lynx1 Capital Management LP's cost basis in TCRX?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.